Articles related to ADJUVANT TREATMENT

In the realm of HER2-positive early breast cancer, achieving a pathological complete response (pCR) post-neoadjuvant therapy has been linked to a markedly reduced risk of recurrence, highlighting the critical role of tailored treatment strategies in improving patient outcomes.

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.

Highlighting a paradigm shift in breast cancer treatment, the NRG Oncology/NSABP B-51/RTOG 1304 study demonstrates that certain patients with node-negative breast cancer post-neoadjuvant chemotherapy may safely omit adjuvant regional nodal irradiation, challenging conventional treatment approaches and potentially improving patient quality of life.

In a significant shift, a new phase 3 trial suggests reconsidering adjuvant radiotherapy after radical prostatectomy, as many patients may not require it long-term, potentially reducing morbidity risks.

This prospective cohort study presents compelling evidence that omitting radiotherapy in women over 55 with specific luminal A breast cancer characteristics may lead to a low incidence of local recurrence at 5 years.

The IDEA study’s findings have led to a notable change in the treatment of stage III colon cancer, with a shift towards a 3-month duration using CAPOX. Explore the detailed analysis and its implications for your practice.